Descripción del proyecto
Hacia una producción farmacéutica europea más sostenible
Los productos farmacéuticos incluyen una amplia variedad de compuestos químicos diseñados para garantizar la seguridad y la eficacia de los tratamientos. Los ingredientes farmacéuticos activos (IFA) son los ingredientes farmacéuticos que proporcionan los efectos beneficiosos sobre la salud que experimentan los pacientes. El objetivo del proyecto TransPharm, financiado con fondos europeos, es producir IFA más sostenibles y ecológicos que reduzcan simultáneamente la huella ambiental y la dependencia de terceros países para su producción. TransPharm ofrecerá herramientas digitales y directrices basadas en inteligencia artificial para el desarrollo de productos farmacéuticos y IFA más ecológicos, así como modelos para determinar sus efectos. El resultado será una industria farmacéutica europea más independiente y competitiva, que puede garantizar un suministro oportuno de tratamientos sostenibles y ecológicos a sus ciudadanos.
Objetivo
TransPharm two-track approach focusses on the one hand on the compounds itself by identifying greener and more sustainable-by-design Active Pharmaceutical Ingredients (APIs) and on the other hand reducing the environmental impact and resilience of the manufacturing process by optimizing the synthesis route of new APIs in continuous flow and by proposing greener alternative solvents.
The aim of the project is to (i) analyse and predict flow behaviour and environmental biodegradability of APIs and their synthesis pathways; (ii) identify greener and more sustainable alternatives to pharmaceutical products / APIs of concern; (iii) reduce the footprint and create important shortcuts in synthetic schemes of APIs; and (iv) assess the sustainability of pharmaceuticals over their entire life cycle. To reach the envisaged aims, the project will deliver four toolboxes (consisting of digital tools and guidelines) for the development of greener pharmaceutical products and APIs. These toolboxes will be used to (v) assess the potential to move towards the transition to greener, more agile pharmaceutical production. In addition, TransPharm will elaborate on the business case for sustainable pharmaceutical products or APIs and what is needed to bring them to the market. The project will also make sure that (vi) key project results and knowledge are properly transferred towards targeted stakeholders.
TransPharm?s outcome contribute to a Europe, that is self-sufficient by reducing dependence on API production in third countries; making the EU healthcare industry more competitive, sustainable and reliable, ensuring timely supply of essential medicines from particularly complex or critical supply and distribution chains and positioning EU as a leader in innovative technologies.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- social scienceseconomics and businessbusiness and managementbusiness models
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- social scienceseconomics and businesseconomicssustainable economy
Palabras clave
Programa(s)
Régimen de financiación
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinador
9000 Gent
Bélgica